| Ytd | -36.99% | |
| 1y | 50.18% |
| Open | 23.34 | Prev Close | 23.89 | Low | 23.34 | High | 24.69 | Mkt Cap | 743.39M |
| Vol | 296.00K | Avg Vol | 396.08K | EPS | -0.44 | P/E | -55.70 | Forward P/E | -13.54 |
| Beta | 1.00 | Short Ratio | 4.27 | Inst. Own | 94.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 21.66 | 200-d Avg | 28.77 | 1yr Est | 41.56 |
CSTL News
FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company
Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurate
Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades &a
Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin
Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP s
Roth Capital analyst Max Masucci initiates coverage on Castle Biosciences (NASDAQ:CSTL) with a Bu
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the pr
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and l
Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $340.000 million-$350.000 million
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.49) per share which met the analys
Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologicall
Canaccord Genuity analyst Kyle Mikson maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and l
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a